Patent US5019372A successfully refreshed from Google Patents.
US5019372A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Magnetically modulated polymeric drug release system
Assignee: Boston Children's Hospital
•
Filing: 1990-09-07
•
Granted: 1991-05-28
•
Expires: 2010-09-07
Abstract
Abstract A magnetically responsive composition for the modulated, sustained administration of a biologically active substance, the composition being in the form of a body sized and shaped for placement in the environment of use, the environment including an aqueous fluid, the body comprising, in admixture, a first phase comprising a biocompatible, plastically deformable, polymeric matrix, the polymeric matrix being insoluble in the environment of use, a second phase having a biologically active substance distributed throughout the matrix to be released to the aqueous fluid outside the matrix, and a third phase comprising a magnetically responsive substance encapsulated within the matrix so that, upon exposure of the body to an oscillating magnetic field, the rate of release of the biologically active substance to the aqueous fluid is increased.
Inventors
- 👤 Judah Folkman
- 👤 Robert S. Langer, Jr.
- 👤 Dean S. T. Hsieh
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 18:12
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61K9/0002; A61K9/0009; A61K9/48; A61K9/50; A61K9/5094
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
166 words
A method of administering a biologically active substance to an animal, e.g., a human, said method comprising preparing an implant for said animal of a medically responsive composition in the form of a body sized and shaped for placement in the environment of use, said environment including an aqueous fluid, said body comprising, in admixture, a first phase comprising a biocompatible, plastically deformable, polymeric matrix, said polymeric matrix being insoluble in the environment of use, a second phase comprising a biologically active substance distributed throughout said matrix to be released to said aqueous fluid outside said matrix, and a third phase comprising a magnetically responsive substance encapsulated within said matrix so that, upon exposure of said body to an oscillating magnetic field, the rate of release of said biologically active substance to said aqueous fluid is increased, in order to subject said body in said animal to an oscillating magnetic field which creates sufficient disturbance to increase the rate of release of said biologically active substance.
Claim 2
Independent Claim
166 words
A method of administering a biologically active substance to an animal, e.g., a human, said method comprising preparing an implant for said animal of a medically responsive composition in the form of a body sized and shaped for placement in the environment of use, said environment including an aqueous fluid, said body comprising, in admixture, a first phase comprising a biocompatible, plastically deformable, polymeric matrix, said polymeric matrix being insoluble in the environment of use, a second phase comprising a biologically active substance distributed throughout said matrix to be released to said aqueous fluid outside said matrix, and a third phase comprising a magnetically responsive substance encapsulated within said matrix so that, upon exposure of said body to an oscillating magnetic field, the rate of release of said biologically active substance to said aqueous fluid is increased, in order to subject said body in said animal to an oscillating magnetic field which creates sufficient disturbance to increase the rate of release of said biologically active substance.
Claim 3
Dependent Claim
21 words
The method of claim 1 wherein said magnetically responsive substance is in the form of discrete particles dispersed throughout said matrix.
Claim 4
Dependent Claim
18 words
The method of claim 1 wherein said magnetically responsive substance is in the form of a single piece.
Claim 5
Dependent Claim
13 words
The method of claim 1 wherein said magnetically responsive substance is a metal.
Claim 6
Dependent Claim
13 words
The method of claim 4 wherein said magnetically responsive substance is stainless steel.
Claim 7
Dependent Claim
14 words
The method of claim 3 wherein said magnetically responsive substance is a permanent magnet.
Claim 8
Dependent Claim
17 words
The method of claim 2 wherein said particles are beads between 0.8 and 1.4 mm in diameter.
Claim 9
Dependent Claim
23 words
The method of claim 1 wherein the ratio, by weight, of said biologically active substance to said polymer is between 1:99 and 90:10.
Claim 10
Dependent Claim
18 words
The method of claim 1 wherein said active substance has a molecular weight of at least 150 daltons.
Claim 11
Dependent Claim
12 words
The method of claim 9 wherein said active substance is a protein.
Claim 12
Dependent Claim
38 words
The method of claim 1 wherein said active substance is a peptide hormone selected from the group consisting of insulin, glucagon, parathyroid, pituitary, calcitonin, vasopressin, renin, prolactin, growth, thyroid stimulating, corticotrophin, follical stimulating, luteinising and chorionic gonadotrophin hormones.
Claim 13
Dependent Claim
11 words
The method of claim 11 wherein said peptide hormone is insulin.
Claim 14
Dependent Claim
12 words
The method of claim 1 wherein said active substance is a steroid.
Claim 15
Dependent Claim
55 words
The method of claim 1 wherein said polymeric matrix is an ethylene vinyl ester copolymer of the general formula: ##STR3## wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 7 carbons, and aryl; m is 10 to 40% by weight, and n is (100-m) % by weight.
Claim 16
Dependent Claim
14 words
The method of claim 1, wherein said polymeric matrix is a crosslinked polymeric matrix.
References Cited (Backward Citations)
US3608549A
Cited
US3659600A
Cited
US4269826A
Cited
US4357259A
Cited
US4267234A
Cited
US4335094A
Cited
US4369226A
Cited
US4247406A
Cited
US4452773A
Cited
US4674680A
Cited
US4652257A
Cited
US4690130A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-05-27 | 1994-11-26 | 1995-05-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-05-27 | 1998-11-26 | 1999-05-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-05-27 | 2002-11-26 | 2003-05-28 | $7700.00 | Window Closed / Lapsed |